Embattled Chinese vaccine maker Changsheng Bio-technology risks delisting as big shareholders are barred from selling shares
Having lost half its market value in the space of seven days after regulators found it had fabricated data for its rabies vaccines, Chinese pharmaceuticals maker Changsheng Bio-technology now faces a further trauma: possible delisting.
The company, which is at the centre of a storm for tampering with production and inspection data related to the vaccine, may be deprived of its listing status for breach of disclosure rules, the Shenzhen Stock Exchange said on Monday night. The bourse has already taken measures barring Changsheng’s major shareholders and executives from selling the stock, it said in a statement on its website.
Shares of Changsheng slumped by the 10 per cent daily limit for a seventh consecutive day to 11.75 yuan at the close on Tuesday, erasing 12.5 billion yuan (US$1.83 billion) in market value.
The company was also found to have sold an unqualified vaccine for the treatment of coughs and colds in infants. The medicine failed a test conducted by the state drug administration.
The scandal has caught the attention of China’s top leaders. Just a day after Premier Li Keqiang dispatched an investigation team, President Xi Jinping interrupted a trip to Africa to order local authorities to conduct an immediate probe and release the findings to the public in a timely manner to ensure social stability.
Trading in the company’s stock will be suspended on Wednesday, and when it restarts on Thursday the company will be categorised as a “special treatment” stock because the company does not expect normal business operations to resume in three months, Changsheng said in an exchange statement after the market closed on Tuesday.
The new status means the daily maximum movement in its share price will be limited to 5 per cent instead of 10 per cent, it said
Mainland Chinese exchanges normally impose special treatment status on companies that have abnormal business operations or financial conditions, or which post losses for two consecutive years.
The fallout also spilled over to stocks of financial institutions. Industrial Securities dropped as much as 5.3 per cent in intraday trading in Shanghai as Changsheng’s historical exchange filings showed two major shareholders had pledged a combined 170.8 million shares to the brokerage for personal loans since April last year. Industrial Securities trimmed losses to close 0.9 per cent lower at 5.28 yuan.
Changsheng vice-chairman Zhang Minghao, son of chairman Gao Junfang, had 160 million shares, or a 17 per cent stake in the company, as collateral with Industrial Securities and another major shareholder, Yu Chenpan, had pledged 10.82 million shares.
Industrial Securities may face having to liquidate Changsheng’s shares, should the stock fall towards a warning level that would trigger a margin call requiring borrowers to add more collateral.